Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics

Theoretical Biology and Medical Modelling

Volumn 6, Issue 1, 2009, Pages

  Bi, Goue Denis Gohore ^a   Li, Jun ^a,b   Nekka, Fahima ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Pharsight   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; MAXIMUM PLASMA CONCENTRATION; PRODUCTIVITY; THEORETICAL MODEL; ANIMAL; ANIMAL FOOD; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; COMPARATIVE STUDY; HUMAN; MICROBIOLOGICAL EXAMINATION; STATISTICS; SWINE;

ANIMAL FEED; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; SWINE;

EID: 68349117108     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-6-10     Document Type: Article

References (40)

1. A Bryskier, antibacterials and antifungals Washington, D.C: ASM Press, André Bryskier, 2005
2. J-L Fauchère, Bactériologie générale et médicale/Jean-Louis Fauchère, Jean-Loup Avril Paris: Ellipses 2002
3. S Robert-Dernuet, Antibiotiques et antibiogrammes/Sabine Robert-Dernuet; préface de Michel Laverdière; [illustrations, Bertrand Lachance Paris: Vigot 1995
4. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. AP MacGowan R Wise, J Antimicrob Chemother 2001 48 Suppl 1 17 28 11420334
5. Who defines resistance? The clinical and economic impact of antimicrobial susceptibility testing breakpoints. JH Jorgensen, Semin Pediatr Infect Dis 2004 15 105 108 10.1053/j.spid.2004.01.014 15185194 (Pubitemid 38881337)
6. In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. DF Sahm C Thornsberry DC Mayfield ME Jones JA Karlowsky, J Clin Microbiol 2002 40 669 674 11825993 10.1128/JCM.40.2.669-674.2002 (Pubitemid 34130903)
7. Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. FS Aliabadi P Lees, Am J Vet Res 2001 62 1979 1989 10.2460/ajvr.2001.62.1979 11763192
8. Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids. FS Aliabadi BH Ali MF Landoni P Lees, Vet J 2003 165 104 118 10.1016/S1090-0233(02)00258-7 12573598 (Pubitemid 37555017)
9. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. PG Ambrose, Pharmacotherapy 2006 26 129 134 10.1592/phco.2006.26.1. 129 16506354 (Pubitemid 43082933)
10. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. D Andes J Anon MR Jacobs WA Craig, Clin Lab Med 2004 24 477 502 10.1016/j.cll.2004.03.009 15177850 (Pubitemid 38737262)
11. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. WA Craig, Clin Infect Dis 1998 26 1 10 quiz 1112 10.1086/516284 9455502
12. Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. GL Drusano, Clin Infect Dis 1998 27 Suppl 1 S111 116 10.1086/514915 9710679
13. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. GL Drusano SL Preston C Hardalo R Hare C Banfield D Andes O Vesga WA Craig, Antimicrob Agents Chemother 2001 45 13 22 11120938 10.1128/AAC.45.1.13-22.2001 (Pubitemid 32039087)
14. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. MR Jacobs, Clin Microbiol Infect 2001 7 589 596 10.1046/j.1198-743x.2001.00295.x 11737083 (Pubitemid 34960355)
15. How can we predict bacterial eradication? MR Jacobs, Int J Infect Dis 2003 7 Suppl 1 S13 20 10.1016/S1201-9712(03)90066-X 12839703 (Pubitemid 36356414)
16. Breakpoints: current practice and future perspectives. JW Mouton, Int J Antimicrob Agents 2002 19 323 331 10.1016/S0924-8579(02)00028-6 11978503 (Pubitemid 34308979)
17. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. JW Mouton MN Dudley O Cars H Derendorf GL Drusano, Int J Antimicrob Agents 2002 19 355 358 10.1016/S0924-8579(02)00031-6 11978507 (Pubitemid 34308981)
18. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. JW Mouton ML van Ogtrop D Andes WA Craig, Antimicrob Agents Chemother 1999 43 2473 2478 10508027
19. Setting and revising antibacterial susceptibility breakpoints. J Turnidge DL Paterson, Clin Microbiol Rev 2007 20 391 408 table of contents 17630331 10.1128/CMR.00047-06 (Pubitemid 47175010)
20. Pharmacological indices in antibiotic therapy. A Barger C Fuhst B Wiedemann, J Antimicrob Chemother 2003 52 893 898 10.1093/jac/dkg482 14613960 (Pubitemid 38008406)
21. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. WA Craig, Diagn Microbiol Infect Dis 1995 22 89 96 10.1016/0732-8893(95)00053-D 7587056
22. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. WA Craig, Eur J Clin Microbiol Infect Dis 1995 14 636 642 10.1007/BF01690745 7588857
23. "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. H Eagle R Fleischman M Levy, N Engl J Med 1953 248 481 488 13036982
24. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. HW Jaffe AL Schroeter GH Reynolds AA Zaidi JE Martin Jr JD Thayer, Antimicrob Agents Chemother 1979 15 587 591 464590
25. [Bactericidal dosie-activity relationships with E. coli, K. pneumoniae and Staph. aureus (author's transl)]. PM Shah Junghanns W Stille, Dtsch Med Wochenschr 1976 101 325 328 174881
26. What do we really know about antibiotic pharmacodynamics? BW Gunderson GH Ross KH Ibrahim JC Rotschafer, Pharmacotherapy 2001 21 302S 318S 10.1592/phco.21.18.302S.33905 11714222
27. Forecasting individual pharmacokinetics. LB Sheiner S Beal B Rosenberg VV Marathe, Clin Pharmacol Ther 1979 26 294 305 466923
28. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. D Czock F Keller, J Pharmacokinet Pharmacodyn 2007 34 727 751 10.1007/s10928-007-9069-x 17906920 (Pubitemid 350165274)
29. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. M Mueller A de la Pena H Derendorf, Antimicrob Agents Chemother 2004 48 369 377 14742182 10.1128/AAC.48.2.369-377.2004 (Pubitemid 38141689)
30. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J Zhi CH Nightingale R Quintiliani, J Pharm Sci 1986 75 1063 1067 10.1002/jps.2600751108 3102718 (Pubitemid 17216550)
31. Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers. LC Strenkoski-Nix A Forrest JJ Schentag DE Nix, J Clin Pharmacol 1998 38 1063 1071 10.1177/009127009803801112 9824789
32. Assessing pharmacokinetic variability directly induced by drug intake behaviour through development of a feeding behaviour-pharmacokinetic model. J Li CE Petit-Jette D Gohore Bi F Fenneteau JR Del Castillo F Nekka, J Theor Biol 2008 251 468 479 10.1016/j.jtbi.2007.11.033 18234231
33. Guidelines for prudent use of antimicrobials and their implications on antibiotic usage in veterinary medicine. FR Ungemach D Muller-Bahrdt G Abraham, Int J Med Microbiol 2006 296 Suppl 41 33 38 10.1016/j.ijmm.2006.01.059 16520092 (Pubitemid 43776699)
34. UA Meyer CC Peck, The drug holiday pattern of noncompliance in clinical trials: challenge to conventional concepts of drug safety and efficacy Washington, DC: Center for Drug Development Science, Georgetown University 1997
35. Chronobiology. Suggestions for integrating it into drug development. JG Harter CC Peck, Ann N Y Acad Sci 1991 618 563 571 10.1111/j.1749-6632.1991. tb27276.x 2006810
36. Pharmacokinetic/pharmacodynamic modeling in drug development. LB Sheiner JL Steimer, Annu Rev Pharmacol Toxicol 2000 40 67 95 10.1146/annurev.pharmtox. 40.1.67 10836128 (Pubitemid 30340674)
37. A pharmacokinetic formalism explicitly integrating the patient drug compliance. J Li F Nekka, J Pharmacokinet Pharmacodyn 2007 34 115 139 10.1007/s10928-006-9036-y 17053982 (Pubitemid 46122551)
38. Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. S Corvaisier PH Maire MY Bouvier d'Yvoire X Barbaut N Bleyzac RW Jelliffe, Antimicrob Agents Chemother 1998 42 1731 1737 9661013
39. The population dynamics of antimicrobial chemotherapy. M Lipsitch BR Levin, Antimicrob Agents Chemother 1997 41 363 373 9021193
40. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. KN Agwuh A MacGowan, J Antimicrob Chemother 2006 58 256 265 10.1093/jac/dkl224 16816396 (Pubitemid 44294934)